Harris E1, Varešlija D2, O’Hara J2, Hill AD2, Young LS2
1RCSI medical student
2Endocrine Oncology Research, Department of Surgery, RCSI
Royal College of Surgeons in Ireland Student Medical Journal 2012;5: 97-98.
Aromatase inhibitors (AIs) are a novel adjuvant endocrine treatment for oestrogen receptor (ER)-positive breast cancer in postmenopausal women. They inhibit the conversion of androgens to oestrogens. In the clinic, AIs have been shown to be superior to tamoxifen (a selective ER modulator), with improved tolerability and increased disease-free survival.1,2 However, prolonged use of AIs can lead to acquired resistance characterised by aberrant ER signalling and crosstalk with growth factor pathways.2 An AI-resistant breast cancer cell line, Let-R, is currently being investigated and demonstrates differential oestrogen regulation of target genes. In resistance, classical genes such as pS2 become oestrogen-independent. However, cyclinD1 remains oestrogen-regulated and appears to be modulated through oestrogen signalling to c-jun N-terminal kinase (JNK) in addition to the ER. This study aims to characterise the Let-R cell line created in the lab and to optimise an ER-α knockdown in Let-R cells.
Endocrine-sensitive parental MCF-7, AI-sensitive MCF-7-Aro and MCF-7-AroR-Let (Let-R) breast cancer cell lines were used to investigate protein expression levels of ER-α, cyclinD1, JNK and c-jun using western blotting. Cells were transfected with 100pmol of ER-α small interfering RNA for 48 hours to optimise the knockdown in Let-R cells.
Let-R cells have higher levels of ER-α, JNK and c-jun compared to MCF-7-Aro cells (Figure 1). CyclinD1 basal levels are elevated in MCF-7-Aro cells compared to Let-R cells (Figure 2). An effective ER-α knockdown in Let-R cells was optimised (Figure 3).
The significant ER-α knockdown achieved in the Let-R cells enables further examination of knockdown effects on protein levels and mRNA expression.
Elevated expression of ER-α in the Let-R cells observed is consistent with the association between AI resistance and ER hypersensitivity.3 In resistant cells, the decrease in basal levels of cyclinD1 may be partly responsible for the lack of regulation of classical genes like pS2, previously detected in the laboratory.4 The elevated levels of JNK and c-jun observed in Let-R cells support the theory of crosstalk between the ER and growth factor pathways in resistance.2 It would be of interest to accompany AI treatments with growth factor inhibitors to further our understanding of endocrine resistance. Understanding such resistance mechanisms will help to create novel biomarkers and therapies to predict and overcome AI resistance.
Kindly sponsored by Breast Cancer Ireland and the RCSI Alumni Fund supported by the Hermitage Medical Clinic.
- Goss PE et al. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71.
- Jordan VC, Brodie AM. Development and evolution of therapies targeted to the oestrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7-25.
- Santen RJ et al. Adaptation to oestradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to oestradiol in breast cancer cells. Adv Exp Med Biol. 2008;630:19-34.
- LodenMetal.ThecyclinD1highandcyclinEhighsubgroupsofbreast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene. 2002;21(30):4680-90.